A Phase I/II Study of an Antitumor Vaccination Using Alpha (1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Hormone Refractory Prostate Cancer

Trial Profile

A Phase I/II Study of an Antitumor Vaccination Using Alpha (1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Hormone Refractory Prostate Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 Dec 2012

At a glance

  • Drugs Prostate cancer vaccine (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 13 Dec 2012 Results published in the Journal of Immunotherapy, according to a NewLink Genetics Corporation.
    • 31 May 2011 Results will be presented at the 47th Annual Meeting of the American Society of Oncology (ASCO-2011).
    • 06 Jul 2006 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top